Treating Depression in Dementia Patients: A Risk or Remedy—A Narrative Review DOI Creative Commons
Sadia Sultan

Geriatrics, Journal Year: 2024, Volume and Issue: 9(3), P. 64 - 64

Published: May 15, 2024

The diagnosis of depression in dementia patients leads to an increase the burden disease. To treat this patient group, antidepressants are frequently used; however, there is not any proof their therapeutic effectiveness, and use may be potentially harmful. This narrative review aims summarize existing evidence regarding role treating patients.

Language: Английский

Prescribing in Older People DOI
David G. Le Couteur, Sarah N. Hilmer, Nicholas Glasgow

et al.

Published: April 10, 2025

Prescribing medications to older people is difficult due comorbidity, limited evidence for efficacy, increased risk of adverse drug reactions, polypharmacy, and altered pharmacokinetics. This article describes the principles underlying clinical geriatric pharmacology including approaches evaluating benefit, adjusting dose age related pharmacokinetic changes. The challenge general practitioner balance an incomplete base efficacy in frail, against problems reactions without denying potentially valuable pharmacotherapeutic interventions.

Language: Английский

Citations

62
Antidepressant medications in dementia: evidence and potential mechanisms of treatment-resistance DOI Creative Commons
Harry Costello, Jonathan P. Roiser, Robert Howard

et al.

Psychological Medicine, Journal Year: 2023, Volume and Issue: 53(3), P. 654 - 667

Published: Jan. 9, 2023

Abstract Depression in dementia is common, disabling and causes significant distress to patients carers. Despite widespread use of antidepressants for depression dementia, there no evidence therapeutic efficacy, their potentially harmful this patient group. has poor outcomes effective treatments are urgently needed. Understanding why ineffective could provide insight into mechanism action aid identification new targets. In review we discuss may be a distinct entity, current theories how work these mechanisms affected by disease processes dementia. We also consider clinicians continue prescribe novel approaches understand identify living with

Language: Английский

Citations

26
Closed-Form Power and Sample Size Calculations for Bayes Factors DOI Creative Commons
Samuel Pawel, Leonhard Held

The American Statistician, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 34

Published: Feb. 18, 2025

Language: Английский

Citations

1
Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer’s disease: systematic review and meta-analysis DOI Creative Commons
Michael David, Martina Del Giovane, Kathy Liu

et al.

Journal of Neurology Neurosurgery & Psychiatry, Journal Year: 2022, Volume and Issue: 93(10), P. 1080 - 1090

Published: July 5, 2022

Background Dysfunction of the locus coeruleus-noradrenergic system occurs early in Alzheimer’s disease, contributing to cognitive and neuropsychiatric symptoms some patients. This offers a potential therapeutic target, although noradrenergic treatments are not currently used clinical practice. Objective To assess efficacy drugs with principally action improving disease. Methods The MEDLINE, Embase ClinicalTrials.gov databases were searched from 1980 December 2021. We generated pooled estimates using random effects meta-analyses. Results included 19 randomised controlled trials (1811 patients), which six judged as ‘good’ quality, seven ‘fair’ ‘poor’. Meta-analysis 10 these studies (1300 patients) showed significant small positive effect on global cognition, measured Mini-Mental State Examination or Disease Assessment Scale—Cognitive Subscale (standardised mean difference (SMD): 0.14, 95% CI: 0.03 0.25, p=0.01; I 2 =0%). No was seen measures attention (SMD: 0.01, −0.17 0.19, p=0.91; =0). apathy meta-analysis eight (425 detected large 0.45, 0.16 0.73, p=0.002; =58%). still present following removal outliers account for heterogeneity across studies. Discussion Repurposing established is most likely offer effective treatment disease general cognition apathy. However, several factors should be considered before designing future trials. These include targeting appropriate patient subgroups understanding dose individual their interactions other minimise risks maximise effects. PROSPERO registeration number CRD42021277500.

Language: Английский

Citations

35
Real-World Evidence on Clinical Outcomes of Commonly Used Antidepressants in Older Adults Initiating Antidepressants for Depression: A Nationwide Cohort Study in Denmark DOI
Kazi Ishtiak‐Ahmed, Katherine L. Musliner, Kaj Sparle Christensen

et al.

American Journal of Psychiatry, Journal Year: 2023, Volume and Issue: 181(1), P. 47 - 56

Published: Oct. 18, 2023

The authors investigated the clinical outcomes of commonly used antidepressants among older adults who initiated first-time for depression by analyzing 1-year risk selected clinically relevant outcomes.

Language: Английский

Citations

17
Emotional and Neuropsychiatric Disorders Associated with Alzheimer's Disease DOI Creative Commons
Kenneth M. Heilman, Stephen E. Nadeau

Neurotherapeutics, Journal Year: 2022, Volume and Issue: 19(1), P. 99 - 116

Published: Jan. 1, 2022

Language: Английский

Citations

24
Comparative efficacy and safety of antidepressant therapy for the agitation of dementia: A systematic review and network meta-analysis DOI Creative Commons
Kaili Chen,

Haiqi Li,

Le Yang

et al.

Frontiers in Aging Neuroscience, Journal Year: 2023, Volume and Issue: 15

Published: March 3, 2023

Dementia is a clinical syndrome commonly seen in the elderly individuals. With prevalence of dementia, incidence neuropsychiatric symptoms dementia patients increasing annually. Agitation, as one symptoms, has serious impact on quality life with dementia. Several antidepressant drugs have been shown to be effective for treating agitated behavior but there are no direct comparisons among those drugs. Therefore, we carried out network meta-analysis (NMA) examine efficacy and safety drugs.We searched eight databases (PubMed, Cochrane Library, Web Science, Embase, Wanfang Database, China National Knowledge Infrastructure, VIP Database biomedical literature service) from their inception 6 November 2022. Randomized controlled trials (RCTs) reporting were included our analysis. The assessment was by two researchers individually analysis based frequency method.Twelve articles 1,146 participants Based outcome agitation score, treatment citalopram (standardized mean difference, SMD = -0.44, 95% confidence interval, CI -0.72 -0.16) showed significant benefits over placebo group. Treatment trazodone (odds ratio, OR 4.58, 1.12-18.69) associated higher risk total adverse events compared treatment.Among this study, probably only optimal intervention, when considering improvement baseline end not statistically difference treatment.https://www.crd.york.ac.uk/prospero/#recordDetails, identifier: PROSPERO, CRD42022320932.

Language: Английский

Citations

12
Functional Magnetic Resonance Imaging in Prurigo Nodularis: A Systematic Review DOI

Xuanyu Zhao,

Jannis M. Mueller,

Simon M. Mueller

et al.

Clinics in Dermatology, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
Past, present, and future of serotonin-targeting therapeutics for Alzheimer’s Disease: perspectives from DNA methylation DOI

Yanzhi Liu,

Luca Aquili, Kah-Hui Wong

et al.

Ageing Research Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 102755 - 102755

Published: April 1, 2025

Language: Английский

Citations

0
The Contribution of the Locus Coeruleus–Noradrenaline System Degeneration during the Progression of Alzheimer’s Disease DOI Creative Commons
Dilek Mercan, Michael T. Heneka

Biology, Journal Year: 2022, Volume and Issue: 11(12), P. 1822 - 1822

Published: Dec. 14, 2022

Alzheimer's disease (AD), which is characterized by extracellular accumulation of amyloid-beta peptide and intracellular aggregation hyperphosphorylated tau, the most common form dementia. Memory loss, cognitive decline disorientation are ultimate consequences neuronal death, synapse loss neuroinflammation in AD. In general, there many brain regions affected but locus coeruleus (LC) one earliest indicators neurodegeneration Since LC main source noradrenaline (NA) brain, degeneration AD leads to decreased NA levels, causing increased neuroinflammation, enhanced amyloid tau burden, phagocytosis impairment cognition long-term synaptic plasticity. this review, we summarized current findings on coeruleus-noradrenaline system its dysfunction now recognized as an important contributor progression.

Language: Английский

Citations

18